Palomino Laboratories (PALX) EBITDA (2023 - 2025)

Palomino Laboratories has disclosed EBITDA across 3 years of filings, most recently posting -$1.6 million for Q3 2025.

• EBITDA for Q3 2025 came in at -$1.6 million, down 129958.51% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.8 million (down 1436.54% YoY), and the FY2024 annual result was -$140080.0, down 66.89% from the prior year.
• EBITDA came in at -$1.6 million for Q3 2025 at Palomino Laboratories, down from -$35548.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1234.0 in Q3 2024 to a low of -$1.6 million in Q3 2025.
• The 3-year median for EBITDA is -$35548.0 (2025), against an average of -$217336.2.
• Across the five-year window, EBITDA surged 97.12% in 2024 and plunged 129958.51% in 2025, its largest moves.
• Palomino Laboratories' EBITDA stood at -$32574.0 in 2023, then sank by 323.53% to -$137962.0 in 2024, then plunged by 1063.31% to -$1.6 million in 2025.
• The last three EBITDA figures came in at -$1.6 million (Q3 2025), -$35548.0 (Q2 2025), and -$17828.0 (Q1 2025), per Business Quant data.